新华制药(000756.SZ)子公司获布洛芬颗粒药品注册证

Group 1 - The core point of the article is that Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Ibuprofen granules from the National Medical Products Administration [1] Group 2 - The approval of the Ibuprofen granules registration certificate signifies a potential expansion in the company's product offerings [1] - This development may enhance the company's market position in the pharmaceutical industry, particularly in the analgesic segment [1] - The registration could lead to increased revenue opportunities for the company as it introduces the new product to the market [1]